Company / Capital Expenditures
ROCKET PHARMACEUTICALS, INC. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$5.9M
FY2025
5-year range
$5.9M / $23.3M
FY2021-FY2025
Trend
-29.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 8 years, ranging from $335,000 in FY2018 to $23M in FY2021.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +32.2%.
Declined from $8M to $6M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -34.2%
- 5-Year CAGR
- +32.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +32.2%, indicating consistent growth.
- In FY2025, capital expenditures decreased 29.9% year-over-year.
- Peak capital expenditures was recorded in FY2021.
- Lowest capital expenditures in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.9M | -29.9% |
| FY2024 | $8.4M | +9.7% |
| FY2023 | $7.6M | -63.0% |
| FY2022 | $20.6M | -11.4% |
| FY2021 | $23.3M | +1501.4% |
| FY2020 | $1.5M | +0.0% |
| FY2019 | $1.5M | +333.7% |
| FY2018 | $335.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026